ArticleBMC microbiology2021
Anticancer and antimicrobial potential of enterocin 12a from Enterococcus faecium.
Article in BMC microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 65 citations in OpenAlex.
- Reproductive tract commensal bacterium Enterococcus faecium supernatant induces DNA damage associated stress responses and suppresses the growth of cervical cancer cells.BMC microbiology · 2026Article
- Current Status and Future Challenges in the Use of Bacteriocins to Modulate Ruminant Gut Microbiota.Probiotics and antimicrobial proteins · 2026Review
- Investigation of probiotic, anticancer and antimicrobial activity of Enterococcus bacteria isolated from the gut microbiota of marine snails.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Review
- Microbial metabolite 5-formamidoimidazole-4-carboxamide ribotide targets METTL1 to inhibit m7G modification of BRCA1 mRNA to inhibit high-grade serous ovarian cancer.Molecular medicine (Cambridge, Mass.) · 2025Article
- Article
- Purification and Characterization of Enterocins A, B, and a Novel High-Mass Bacteriocin fromAntibiotics (Basel, Switzerland) · 2025Article
- Synthesis and computational investigation of novel 2-mercaptoimidazolones as dual antimicrobial and anti-proliferative agents with potential multitargeting kinase inhibitory activity.Scientific reports · 2025Article
- Probiotics: A New Approach for the Prevention and Treatment of Cervical Cancer.Probiotics and antimicrobial proteins · 2025Review
- Characterisation of gut microbiota in Malaysian cancer patients using V3-V4 region of 16S rRNA gene sequencing.Scientific reports · 2025Article
- Toward safer and sustainable food preservation: a comprehensive review of bacteriocins in the food industry.Bioscience reports · 2025Review
- A review on the ecological niche and functional properties of enterococci in health promotion.Current research in food science · 2025Review
- Bacteriocin Mining inFoods (Basel, Switzerland) · 2024Article
- Recent Progress in Terrestrial Biota Derived Antibacterial Agents for Medical Applications.Molecules (Basel, Switzerland) · 2024Review
- Emerging lactic acid bacteria bacteriocins as anti-cancer and anti-tumor agents for human health.Heliyon · 2024Review
- Bacteriocins: potentials and prospects in health and agrifood systems.Archives of microbiology · 2024Review
- Article
- Appraisal of postbiotics in cancer therapy.Frontiers in pharmacology · 2024Review
- An overview of the production and use ofOpen life sciences · 2024Review
- Probiotic potentials of lactic acid bacteria isolated from Egyptian fermented food.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIncrease in the number of infections caused by Gram-negative bacteria in neutropenic cancer patients has prompted the search for novel therapeutic agents having dual anticancer and antimicrobial properties. Bacteriocins are cationic proteins of prokaryotic origin that have emerged as one of the most promising alternative antimicrobial agents with applications as food preservatives and therapeutic agents. Apart from their antimicrobial activities, bacteriocins are also being explored for their anticancer potential.
resultsIn this study, a broad-spectrum, cell membrane-permeabilizing enterocin with a molecular weight of 65 kDa was purified and characterized from the culture supernatant of vaginal Enterococcus faecium 12a. Enterocin 12a inhibited multidrug-resistant strains of various Gram-negative pathogens such as Salmonella enterica, Shigella flexneri, Vibrio cholerae, Escherichia coli and Gram-positive, Listeria monocytogenes, but had no activities against different strains of gut lactobacilli. The mass spectrometric analysis showed that the enterocin 12a shared partial homology with 4Fe-4S domain-containing redox protein of E. faecalis R712. Further, enterocin 12a selectively inhibited the proliferation of various human cancer cell lines in a dose-dependent manner but not that of normal human peripheral blood mononuclear cells. Enterocin 12a-treated cancer cells showed apoptosis-like morphological changes.
conclusionEnterocin 12a is a novel bacteriocin that has anticancer properties against human cell lines and negligible activity towards non-malignant cells. Therefore, it should be further evaluated for its anticancer potential in animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.